
<document id="DBMI.pac186" origId="pac186">
	<sentence id="DBMI.pac186.s0" origId="s0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nSimvastatin is a prodrug and is hydrolyzed to its active 3-hydroxyacid form, simvastatin acid, after administration."/>
	<sentence id="DBMI.pac186.s1" origId="s1" text="Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol."/>
	<sentence id="DBMI.pac186.s2" origId="s2" text="In addition, simvastatin reduces VLDL and TG and increases HDL-C.\n\n12.2 Pharmacodynamics\n\nEpidemiological studies have demonstrated that elevated levels of total-C, LDL-C, as well as decreased levels of HDL-C are associated with the development of atherosclerosis and increased cardiovascular risk."/>
	<sentence id="DBMI.pac186.s3" origId="s3" text="Lowering LDL-C decreases this risk."/>
	<sentence id="DBMI.pac186.s4" origId="s4" text="However, the independent effect of raising HDL-C or lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been determined."/>
	<sentence id="DBMI.pac186.s5" origId="s5" text="12.3 Pharmacokinetics\n\nSimvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding -hydroxyacid, a potent inhibitor of HMG-CoA reductase."/>
	<sentence id="DBMI.pac186.s6" origId="s6" text="Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the -hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin."/>
	<sentence id="DBMI.pac186.s7" origId="s7" text="Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces."/>
	<sentence id="DBMI.pac186.s8" origId="s8" text="Plasma concentrations of total radioactivity (simvastatin plus 14C-metabolites) peaked at 4 hours and declined rapidly to about 10% of peak by 12 hours postdose."/>
	<sentence id="DBMI.pac186.s9" origId="s9" text="Since simvastatin undergoes extensive first-pass extraction in the liver, the availability of the drug to the general circulation is low (&lt;5%)."/>
	<sentence id="DBMI.pac186.s10" origId="s10" text="Both simvastatin and its -hydroxyacid metabolite are highly bound (approximately 95%) to human plasma proteins."/>
	<sentence id="DBMI.pac186.s11" origId="s11" text="Rat studies indicate that when radiolabeled simvastatin was administered, simvastatin-derived radioactivity crossed the blood-brain barrier."/>
	<sentence id="DBMI.pac186.s12" origId="s12" text="The major active metabolites of simvastatin present in human plasma are the -hydroxyacid of simvastatin and its 6-hydroxy, 6-hydroxymethyl, and 6-exomethylene derivatives."/>
	<sentence id="DBMI.pac186.s13" origId="s13" text="Peak plasma concentrations of both active and total inhibitors were attained within 1.3 to 2.4 hours postdose."/>
	<sentence id="DBMI.pac186.s14" origId="s14" text="While the recommended therapeutic dose range is 5 to 80 mg/day, there was no substantial deviation from linearity of AUC of inhibitors in the general circulation with an increase in dose to as high as 120 mg."/>
	<sentence id="DBMI.pac186.s15" origId="s15" text="Relative to the fasting state, the plasma profile of inhibitors was not affected when simvastatin was administered immediately before an American Heart Association recommended low-fat meal."/>
	<sentence id="DBMI.pac186.s16" origId="s16" text="In a study including 16 elderly patients between 70 and 78 years of age who received simvastatin 40 mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30 years of age."/>
	<sentence id="DBMI.pac186.s17" origId="s17" text="Clinical study experience in the elderly (n=1 522), suggests that there were no overall differences in safety between elderly and younger patients [see Use in Specific Populations (8.5)]."/>
	<sentence id="DBMI.pac186.s18" origId="s18" text="Kinetic studies with another statin, having a similar principal route of elimination, have suggested that for a given dose level higher systemic exposure may be achieved in patients with severe renal insufficiency (as measured by creatinine clearance)."/>
	<sentence id="DBMI.pac186.s19" origId="s19" text="Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins.">
		<entity charOffset="3444-3457" id="DBMI.pac186.s19.e0" origId="s19.e0" text="cyclosporine " type="Active ingredient"/>
		<entity charOffset="3528-3540" id="DBMI.pac186.s19.e1" origId="s19.e1" text="simvastatin " type="Active ingredient"/>
		<pair e1="DBMI.pac186.s19.e0" e2="DBMI.pac186.s19.e1" id="DBMI.pac186.s19.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="simvastatin " precipitant="cyclosporine "/>
		<pair e1="DBMI.pac186.s19.e1" e2="DBMI.pac186.s19.e0" id="DBMI.pac186.s19.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac186.s20" origId="s20" text="The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4."/>
	<sentence id="DBMI.pac186.s21" origId="s21" text="The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma."/>
	<sentence id="DBMI.pac186.s22" origId="s22" text="Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)]."/>
	<sentence id="DBMI.pac186.s23" origId="s23" text="In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.">
		<entity charOffset="3928-3940" id="DBMI.pac186.s23.e0" origId="s23.e0" text="simvastatin " type="Active ingredient"/>
		<entity charOffset="4065-4078" id="DBMI.pac186.s23.e1" origId="s23.e1" text="erythromycin " type="Active ingredient"/>
		<entity charOffset="4051-4061" id="DBMI.pac186.s23.e2" origId="s23.e2" text="midazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac186.s23.e0" e2="DBMI.pac186.s23.e1" id="DBMI.pac186.s23.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="erythromycin " precipitant="simvastatin "/>
		<pair e1="DBMI.pac186.s23.e0" e2="DBMI.pac186.s23.e1" id="DBMI.pac186.s23.p1" interaction="true" interactionPhraseType="Quantitative" modality="Negative" object="erythromycin " precipitant="simvastatin "/>
		<pair e1="DBMI.pac186.s23.e0" e2="DBMI.pac186.s23.e2" id="DBMI.pac186.s23.p2" interaction="true" interactionPhraseType="Quantitative" modality="Negative" object="midazolam " precipitant="simvastatin "/>
		<pair e1="DBMI.pac186.s23.e1" e2="DBMI.pac186.s23.e0" id="DBMI.pac186.s23.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac186.s23.e1" e2="DBMI.pac186.s23.e2" id="DBMI.pac186.s23.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac186.s23.e2" e2="DBMI.pac186.s23.e0" id="DBMI.pac186.s23.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac186.s23.e2" e2="DBMI.pac186.s23.e1" id="DBMI.pac186.s23.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac186.s24" origId="s24" text="This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4."/>
	<sentence id="DBMI.pac186.s25" origId="s25" text="Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.">
		<entity charOffset="4261-4273" id="DBMI.pac186.s25.e0" origId="s25.e0" text="simvastatin " type="Active ingredient"/>
		<entity charOffset="4363-4371" id="DBMI.pac186.s25.e1" origId="s25.e1" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac186.s25.e0" e2="DBMI.pac186.s25.e1" id="DBMI.pac186.s25.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digoxin " precipitant="simvastatin "/>
		<pair e1="DBMI.pac186.s25.e1" e2="DBMI.pac186.s25.e0" id="DBMI.pac186.s25.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentencespan id="DBMI.pac186.sp0" origId="sp0" text="12 CLINICAL PHARMACOLOGY\n\n12.1 Mechanism of Action\n\nSimvastatin is a prodrug and is hydrolyzed to its active 3-hydroxyacid form, simvastatin acid, after administration. Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol. In addition, simvastatin reduces VLDL and TG and increases HDL-C.\n\n12.2 Pharmacodynamics\n\nEpidemiological studies have demonstrated that elevated levels of total-C, LDL-C, as well as decreased levels of HDL-C are associated with the development of atherosclerosis and increased cardiovascular risk."/>
	<sentencespan id="DBMI.pac186.sp1" origId="sp1" text="Lowering LDL-C decreases this risk. However, the independent effect of raising HDL-C or lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been determined. 12.3 Pharmacokinetics\n\nSimvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding -hydroxyacid, a potent inhibitor of HMG-CoA reductase."/>
	<sentencespan id="DBMI.pac186.sp2" origId="sp2" text="Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the -hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of simvastatin. Following an oral dose of 14C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces. Plasma concentrations of total radioactivity (simvastatin plus 14C-metabolites) peaked at 4 hours and declined rapidly to about 10% of peak by 12 hours postdose."/>
	<sentencespan id="DBMI.pac186.sp3" origId="sp3" text="Since simvastatin undergoes extensive first-pass extraction in the liver, the availability of the drug to the general circulation is low (&lt;5%). Both simvastatin and its -hydroxyacid metabolite are highly bound (approximately 95%) to human plasma proteins. Rat studies indicate that when radiolabeled simvastatin was administered, simvastatin-derived radioactivity crossed the blood-brain barrier."/>
	<sentencespan id="DBMI.pac186.sp4" origId="sp4" text="The major active metabolites of simvastatin present in human plasma are the -hydroxyacid of simvastatin and its 6-hydroxy, 6-hydroxymethyl, and 6-exomethylene derivatives. Peak plasma concentrations of both active and total inhibitors were attained within 1.3 to 2.4 hours postdose. While the recommended therapeutic dose range is 5 to 80 mg/day, there was no substantial deviation from linearity of AUC of inhibitors in the general circulation with an increase in dose to as high as 120 mg."/>
	<sentencespan id="DBMI.pac186.sp5" origId="sp5" text="Relative to the fasting state, the plasma profile of inhibitors was not affected when simvastatin was administered immediately before an American Heart Association recommended low-fat meal. In a study including 16 elderly patients between 70 and 78 years of age who received simvastatin 40 mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30 years of age. Clinical study experience in the elderly (n=1 522), suggests that there were no overall differences in safety between elderly and younger patients [see Use in Specific Populations (8.5)]."/>
	<sentencespan id="DBMI.pac186.sp6" origId="sp6" text="Kinetic studies with another statin, having a similar principal route of elimination, have suggested that for a given dose level higher systemic exposure may be achieved in patients with severe renal insufficiency (as measured by creatinine clearance). Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of statins. The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.">
		<entity charOffset="3444-3457" id="DBMI.pac186.sp6.e0" origId="sp6.e0" text="cyclosporine " type="Active ingredient"/>
		<entity charOffset="3528-3540" id="DBMI.pac186.sp6.e1" origId="sp6.e1" text="simvastatin " type="Active ingredient"/>
		<pair e1="DBMI.pac186.sp6.e0" e2="DBMI.pac186.sp6.e1" id="DBMI.pac186.sp6.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="simvastatin " precipitant="cyclosporine "/>
		<pair e1="DBMI.pac186.sp6.e1" e2="DBMI.pac186.sp6.e0" id="DBMI.pac186.sp6.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac186.sp7" origId="sp7" text="The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma. Inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy [see Warnings and Precautions (5.1) and Drug Interactions (7.1)]. In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin.">
		<entity charOffset="3928-3940" id="DBMI.pac186.sp7.e0" origId="sp7.e0" text="simvastatin " type="Active ingredient"/>
		<entity charOffset="4065-4078" id="DBMI.pac186.sp7.e1" origId="sp7.e1" text="erythromycin " type="Active ingredient"/>
		<entity charOffset="4051-4061" id="DBMI.pac186.sp7.e2" origId="sp7.e2" text="midazolam " type="Active ingredient"/>
		<pair e1="DBMI.pac186.sp7.e0" e2="DBMI.pac186.sp7.e1" id="DBMI.pac186.sp7.p0" interaction="true" interactionPhraseType="Qualitative" modality="Negative" object="erythromycin " precipitant="simvastatin "/>
		<pair e1="DBMI.pac186.sp7.e0" e2="DBMI.pac186.sp7.e1" id="DBMI.pac186.sp7.p1" interaction="true" interactionPhraseType="Quantitative" modality="Negative" object="erythromycin " precipitant="simvastatin "/>
		<pair e1="DBMI.pac186.sp7.e0" e2="DBMI.pac186.sp7.e2" id="DBMI.pac186.sp7.p2" interaction="true" interactionPhraseType="Quantitative" modality="Negative" object="midazolam " precipitant="simvastatin "/>
		<pair e1="DBMI.pac186.sp7.e1" e2="DBMI.pac186.sp7.e0" id="DBMI.pac186.sp7.p3" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac186.sp7.e1" e2="DBMI.pac186.sp7.e2" id="DBMI.pac186.sp7.p4" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac186.sp7.e2" e2="DBMI.pac186.sp7.e0" id="DBMI.pac186.sp7.p5" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
		<pair e1="DBMI.pac186.sp7.e2" e2="DBMI.pac186.sp7.e1" id="DBMI.pac186.sp7.p6" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac186.sp8" origId="sp8" text="This indicates that simvastatin is not an inhibitor of CYP3A4, and, therefore, is not expected to affect the plasma levels of other drugs metabolized by CYP3A4. Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL.">
		<entity charOffset="4261-4273" id="DBMI.pac186.sp8.e0" origId="sp8.e0" text="simvastatin " type="Active ingredient"/>
		<entity charOffset="4363-4371" id="DBMI.pac186.sp8.e1" origId="sp8.e1" text="digoxin " type="Active ingredient"/>
		<pair e1="DBMI.pac186.sp8.e0" e2="DBMI.pac186.sp8.e1" id="DBMI.pac186.sp8.p0" interaction="true" interactionPhraseType="Quantitative" modality="Positive" object="digoxin " precipitant="simvastatin "/>
		<pair e1="DBMI.pac186.sp8.e1" e2="DBMI.pac186.sp8.e0" id="DBMI.pac186.sp8.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
</document>
